Exploring the effects of Factor Xa inhibitors on thrombin generation in people with haemophilia
Optimal management of cardiovascular disease (CVD) in people with haemophilia (PWH) is a growing issue, given the continuing improvement in life expectancy among PWH. The evolving treatment paradigms targeting higher trough levels and the advent of non-factor replacement therapies (NFRT) means much of the ‘protection’ PWH were thought to have against CVD may be lost. There is a paucity of evidence regarding the safety of using anticoagulants in PWH. We designed a study assessing the thrombin generation (TG) of PWH of different severities and treatments, compared to non-haemophilia patients receiv ing a Factor Xa (FXa) inhibitor (apixaban or rivaroxaban), healthy controls, and assessing TG parameters of adding FXa inhibitor to the plasma of PWH receiving emicizumab prophylaxis.
Source: Thrombosis Research - Category: Hematology Authors: Caroline Dix, James D. McFadyen, Huyen A. Tran Tags: Full Length Article Source Type: research
More News: Cardiology | Cardiovascular | Haemophilia | Heart | Hematology | Hemophilia | Study | Thrombosis